Want to see TVGN full AI Analyst Report?
TVGN Stock Chart & Stats
$0.32
-$0.17(-11.18%)
At close: 4:00 PM EST
$0.32
-$0.17(-11.18%)
Day’s Range― - ―
52-Week Range$4.14 - $71.00
Previous CloseN/A
Volume2.03M
Average Volume (3M)557.82K
Market Cap
$21.35M
Enterprise Value$43.31M
Total Cash (Recent Filing)$692.30K
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.84
Shares Outstanding4,219,343
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap2.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-299.01
Enterprise Value/Ebitda-2.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary T‑cell PlatformA proprietary precision T‑cell platform is a durable strategic asset: platform-based R&D can yield multiple therapeutic candidates across viral and oncology indications, spreading scientific risk and enabling recurring value creation if one or more candidates reach late‑stage trials or partnerships.
Reduced Debt BurdenA sharp reduction in debt improves near‑term financial flexibility by lowering fixed financing obligations and reducing default risk. For a development‑stage biotech, lower debt eases pressure to raise dilutive capital quickly and provides marginally more runway to advance clinical programs.
Cash Burn Tracks LossesOperating cash outflows that broadly mirror accounting losses indicate relatively predictable burn and disciplined cash conversion. That alignment helps management forecast financing needs and conduct pipeline prioritization, a constructive trait when raising capital over the medium term.
Bears Say
No Revenue / Persistent LossesThe absence of commercial revenue and sustained operating losses indicate the business remains wholly pre‑commercial and reliant on financing. This structural cash‑consuming model elevates execution and funding risk until clinical success or partnerships generate recurring revenue.
Negative Stockholders' EquityPersistently negative shareholders' equity is a structural solvency concern that limits traditional financing options, can trigger covenant or listing issues, and increases dilution risk as the company must rely on equity or high‑cost financing to fund development programs.
Nasdaq Market Value NoncomplianceNasdaq noncompliance is a material structural risk: prolonged failure to regain thresholds could force a market transfer or delisting, reducing liquidity, increasing investor uncertainty, and constraining access to equity financing that the loss‑making company depends on.
Tevogen Bio Holdings News
TVGN FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was $4.13 and its highest was $71.00 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is $21.35M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Aug 13, 2026 which is in 32 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Jun 03, 2026. The company reported -$1.612 earnings per share for the quarter, beating the consensus estimate of -$2.64 by $1.028.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 4,219,343 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -$1.612 in its last earnings report, beating expectations of -$2.64. Following the earnings report the stock price went up 6.966%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in TVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―